Lipoprotein(a) levels, which are largely determined by genetics, appear to fluctuate over time, particularly in individuals with moderately elevated concentrations, a UK Biobank analysis shows. People ...

A debate on whether testing Lp(a) levels is actionable in primary prevention today offered lively discussion at the 2024 Congress of the American Society for Preventive Cardiology, being held in Salt ...

Results are now out for A-level students in England, Wales and Northern Ireland, after they were released at 08:00 BST on Thursday morning. Here is your guide to this year's results, appeals and ...

A clinical trial testing muvalaplin, a novel oral medication, was able to safely and effectively lower high levels of lipoprotein (a), according to late-breaking science presented today at the ...

Among people with low levels of LDL cholesterol—even those who achieve very large absolute reductions with statin therapy—higher levels of lipoprotein(a) are associated with an increased risk of ...

CHICAGO -- Novel small interfering RNA (siRNA) agent lepodisiran drastically cut levels of lipoprotein(a), or Lp(a), in the phase II ALPACA trial. The 400-mg dose cut Lp(a) by 93.9 percentage points ...